Gene Therapy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, China, Japan - Size and Forecast 2023-2027

Published: Feb 2023 Pages: 161 SKU: IRTNTR73059

Gene Therapy Market Forecast 2023-2027

Gene Therapy Market size is estimated to grow by USD 4,613.9 million between 2022 and 2027 accelerating at a CAGR of 19.91% during the forecast period.

The growth of the market depends on several factors, including the increase in special drug designations, the benefits associated, and the increasing prevalence of chronic diseases. Factors such as high treatment costs may hinder the demand of the market. However, market trends such as research in gene therapy for CVDs and orphan diseases and rapid demand potential in developing economies will propel the market growth.

What will be the size of the Gene Therapy Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Dynamics

Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Driver

The increase in special drug designations is one of the key drivers supporting the market growth. Most of the programs received designations such as orphan drug designation, fast track designation, and breakthrough designation from the US FDA, the EMA, and other regulatory bodies, for the treatment of certain disorders. These designations provide certain benefits to pharmaceutical companies.

For instance, orphan drug designation is given to the drugs that are being developed to treat rare diseases that affect less than 200,000 people in the US. When a drug receives orphan drug designation, the company receives market exclusivity for ten years instead of seven years. Orphan drug status also helps the company with tax benefits in the next research by the company. Such benefits of special drug designations will drive the market during the forecast period.

Significant Trends

Growing research in gene therapy for CVDs and orphan diseases is one of the key market trends that is contributing to the market growth. Various research organizations and institutes play a significant role in the market. The market is witnessing continuous change owing to mergers and acquisitions (M&A). Small companies and research institutes have collaborations and partnerships with the giant leaders of the pharmaceutical industry. This further helps the market leaders to expand their area of research and product portfolio.

On the other hand, it proves to be a big financial support for small and new companies. Some of the major collaborations in the market are the collaboration between Celgene and Bluebird Bio and Adapt Immune and GlaxoSmithKline. Such growing research will boost the market during the forecast period.

Major Challenge

High treatment costs is one of the factors hindering the market growth. The cost of gene therapies is in the range of USD  300,000- USD 1,200,000. It works differently on various individuals, and unlike other biological molecules and small molecules, it needs to be tailored for each individual separately. The mutated gene in the cell is extracted from the patient and is modified in the laboratory. The modified stem cells are introduced into the patient using a viral vector administered through the intravenous route. This increases the cost of manufacturing, thus increasing the overall cost. Such increasing costs will be a challenging factor for the demand of the market during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Gene Therapy Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abeona Therapeutics Inc.: The company offers Phase 3 VIITAL Clinical Trial of EB 101. Also, under this segment, the company offers solutions to treat diseases including cancer, genetic diseases, and infectious diseases.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Adaptimmune Therapeutics plc
  • Adverum Biotechnologies Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio Inc.
  • Editas Medicine Inc.
  • ElevateBio
  • F. Hoffmann La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences Inc.
  • Novartis AG
  • Orchard Therapeutics Plc
  • Poseida Therapeutics Inc.
  • Sangamo Therapeutics Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market share growth by the oncology segment will be significant during the forecast period. In this segment, owing to the high success rate of treatment, many companies are focusing on developing novel gene therapies. For instance, Novartis received approval from the US FDA to launch Kymriah (tisagenlecleucel) for the treatment of B-cell precursor acute lymphoblastic leukemia. Kymriah is a CAR T-cell-based gene therapy. It showed positive results in clinical trials in humans. The global market by oncology is expected to increase the demand during the forecast period owing to the entry of new therapies into the market globally.

Get a glance at the market contribution of various segments Request a PDF Sample

The oncology segment was valued at USD 694.96 million in 2017 and continue to grow by 2021. The global oncology drugs market has a huge unmet demand for the treatment of various indications. Also, the increasing prevalence of cancer indications led pharmaceutical companies and research organizations to conduct substantial research on the development of drugs for these indications. The lack of efficacy of the small molecules and biological molecules made the companies move toward effective treatment options. Several approaches were developed for the management of cancer, including anti-angiogenic gene therapy, suicide gene therapy, immunotherapy, siRNA therapy, pro-apoptotic gene therapy, oncolytic virotherapy, and gene-directed enzyme pro-drug therapy..

Which are the Key Regions for the Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market share during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The US has become a lucrative market for investments in the market in North America. This is because of the funding provided by government departments such as the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) to small-scale industries and companies that are focusing on developing novel products. The increasing funds from government and private organizations will foster the development of gene therapies during the forecast period. Due to the funding, about 18 clinical trials and 17 startup biotechnology companies are being set up in the country. Therefore, such funding is expected to contribute to the market demand during the forecast period. 

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the market growth and trends opportunities from 2017 to 2027. 

  • Therapy Area Outlook (USD Million, 2017 - 2027)
    • Oncology
    • CNS
    • Ophthalmology
    • Rare diseases
    • Others
  • Delivery Mode Outlook (USD Million, 2017 - 2027)
    • In vivo
    • Ex vivo
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Rest of the world

Market Analyst Overview

The Market is rapidly advancing, driven by innovations in biomedicine, genetic engineering, and the development of novel therapies for various genetic disorders. They hold promise for treating conditions like Beta thalassemia, Duchenne muscular dystrophy, and spinal muscular atrophy by targeting specific genes and correcting genetic abnormalities.

CRISPR/Cas9 and lentivirus vectors are gene editing technologies. These technologies are used to deliver therapeutic genes to target cells, addressing issues like muscle atrophy, neurodegenerative diseases, and blood abnormalities. Despite regulatory challenges, the market is poised for growth, fueled by venture capital financing and partnerships with organizations like the National Institute of Standards and Technology and the United States Department of Commerce. With advancements in gene delivery and expression, gene therapy is becoming a viable treatment option for a wide range of genetic disorders, offering new hope for patients and families affected by these conditions.

Gene Therapy Market Scope

Report Coverage

Details

Page number

161

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 19.91%

Market growth 2023-2027

USD 4,613.9 million

Market structure

Fragmented

YoY growth 2022-2023(%)

16.76

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Canada, UK, China, and Japan

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., bluebird bio Inc., Editas Medicine Inc., ElevateBio, F. Hoffmann La Roche Ltd., Generation Bio Co., Gilead Sciences Inc., Novartis AG, Orchard Therapeutics Plc, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Sibiono GeneTech Co. Ltd., Syncona Ltd., uniQure NV, and Voyager Therapeutics Inc.

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.

Customization purview

If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Area
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Delivery Mode
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global gene therapy market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global gene therapy market 2017 - 2021 ($ million)
    • 4.2 Therapy area Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Therapy area Segment 2017 - 2021 ($ million)
    • 4.3 Delivery mode Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Delivery mode Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Therapy Area

    • 6.1 Market segments
      • Exhibit 30: Chart on Therapy Area - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Therapy Area - Market share 2022-2027 (%)
    • 6.2 Comparison by Therapy Area
      • Exhibit 32: Chart on Comparison by Therapy Area
      • Exhibit 33: Data Table on Comparison by Therapy Area
    • 6.3 Oncology - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Oncology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Oncology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Oncology - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Oncology - Year-over-year growth 2022-2027 (%)
    • 6.4 CNS - Market size and forecast 2022-2027
      • Exhibit 38: Chart on CNS - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on CNS - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on CNS - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on CNS - Year-over-year growth 2022-2027 (%)
    • 6.5 Ophthalmology - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Ophthalmology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Ophthalmology - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Ophthalmology - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Ophthalmology - Year-over-year growth 2022-2027 (%)
    • 6.6 Rare diseases - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Rare diseases - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on Rare diseases - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on Rare diseases - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Rare diseases - Year-over-year growth 2022-2027 (%)
    • 6.7 Others - Market size and forecast 2022-2027
      • Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.8 Market opportunity by Therapy Area
      • Exhibit 54: Market opportunity by Therapy Area ($ million)

    7 Market Segmentation by Delivery Mode

    • 7.1 Market segments
      • Exhibit 55: Chart on Delivery Mode - Market share 2022-2027 (%)
      • Exhibit 56: Data Table on Delivery Mode - Market share 2022-2027 (%)
    • 7.2 Comparison by Delivery Mode
      • Exhibit 57: Chart on Comparison by Delivery Mode
      • Exhibit 58: Data Table on Comparison by Delivery Mode
    • 7.3 In vivo - Market size and forecast 2022-2027
      • Exhibit 59: Chart on In vivo - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on In vivo - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on In vivo - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on In vivo - Year-over-year growth 2022-2027 (%)
    • 7.4 Ex vivo - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Ex vivo - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Ex vivo - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Ex vivo - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Ex vivo - Year-over-year growth 2022-2027 (%)
    • 7.5 Market opportunity by Delivery Mode
      • Exhibit 67: Market opportunity by Delivery Mode ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 69: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 70: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 71: Chart on Geographic comparison
      • Exhibit 72: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 97: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 105: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 109: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 110: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 112: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 113: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 114: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 115: Matrix on vendor position and classification
            • 12.3 Abeona Therapeutics Inc.
              • Exhibit 116: Abeona Therapeutics Inc. - Overview
              • Exhibit 117: Abeona Therapeutics Inc. - Product / Service
              • Exhibit 118: Abeona Therapeutics Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 119: Amgen Inc. - Overview
              • Exhibit 120: Amgen Inc. - Product / Service
              • Exhibit 121: Amgen Inc. - Key offerings
            • 12.5 Astellas Pharma Inc.
              • Exhibit 122: Astellas Pharma Inc. - Overview
              • Exhibit 123: Astellas Pharma Inc. - Product / Service
              • Exhibit 124: Astellas Pharma Inc. - Key offerings
            • 12.6 Biogen Inc.
              • Exhibit 125: Biogen Inc. - Overview
              • Exhibit 126: Biogen Inc. - Product / Service
              • Exhibit 127: Biogen Inc. - Key offerings
            • 12.7 bluebird bio Inc.
              • Exhibit 128: bluebird bio Inc. - Overview
              • Exhibit 129: bluebird bio Inc. - Product / Service
              • Exhibit 130: bluebird bio Inc. - Key offerings
            • 12.8 ElevateBio
              • Exhibit 131: ElevateBio - Overview
              • Exhibit 132: ElevateBio - Product / Service
              • Exhibit 133: ElevateBio - Key offerings
            • 12.9 F. Hoffmann La Roche Ltd.
              • Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.10 Generation Bio Co.
              • Exhibit 139: Generation Bio Co. - Overview
              • Exhibit 140: Generation Bio Co. - Product / Service
              • Exhibit 141: Generation Bio Co. - Key offerings
            • 12.11 Gilead Sciences Inc.
              • Exhibit 142: Gilead Sciences Inc. - Overview
              • Exhibit 143: Gilead Sciences Inc. - Product / Service
              • Exhibit 144: Gilead Sciences Inc. - Key news
              • Exhibit 145: Gilead Sciences Inc. - Key offerings
            • 12.12 Novartis AG
              • Exhibit 146: Novartis AG - Overview
              • Exhibit 147: Novartis AG - Business segments
              • Exhibit 148: Novartis AG - Key offerings
              • Exhibit 149: Novartis AG - Segment focus
            • 12.13 Orchard Therapeutics Plc
              • Exhibit 150: Orchard Therapeutics Plc - Overview
              • Exhibit 151: Orchard Therapeutics Plc - Product / Service
              • Exhibit 152: Orchard Therapeutics Plc - Key offerings
            • 12.14 Poseida Therapeutics Inc.
              • Exhibit 153: Poseida Therapeutics Inc. - Overview
              • Exhibit 154: Poseida Therapeutics Inc. - Product / Service
              • Exhibit 155: Poseida Therapeutics Inc. - Key offerings
            • 12.15 Sibiono GeneTech Co. Ltd.
              • Exhibit 156: Sibiono GeneTech Co. Ltd. - Overview
              • Exhibit 157: Sibiono GeneTech Co. Ltd. - Product / Service
              • Exhibit 158: Sibiono GeneTech Co. Ltd. - Key offerings
            • 12.16 uniQure NV
              • Exhibit 159: uniQure NV - Overview
              • Exhibit 160: uniQure NV - Product / Service
              • Exhibit 161: uniQure NV - Key offerings
            • 12.17 Voyager Therapeutics Inc.
              • Exhibit 162: Voyager Therapeutics Inc. - Overview
              • Exhibit 163: Voyager Therapeutics Inc. - Product / Service
              • Exhibit 164: Voyager Therapeutics Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 165: Inclusions checklist
                • Exhibit 166: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 167: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 168: Research methodology
                • Exhibit 169: Validation techniques employed for market sizing
                • Exhibit 170: Information sources
              • 13.5 List of abbreviations
                • Exhibit 171: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              gene therapy market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis